Next Article in Journal
Comparison of Cameriere’s and Demirjian’s Methods of Age Estimation among Children in Kerala: A Pilot Study
Previous Article in Journal
Studying the Effects of Primary Arthroplasty on Post-Treatment Results among Elderly Patients with Pertrochanteric Fracture
 
 
Clinics and Practice is published by MDPI from Volume 11 Issue 1 (2021). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with PAGEPress.
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Case Report

Neuroleptic Malignant Syndrome: A Case Responding to Electroconvulsive Therapy Plus Bupropion

by
Quintí Foguet-Boreu
1,2,3,*,
Montse Coll-Negre
1,
Montse Serra-Millàs
1,4 and
Miquel Cavalleria-Verdaguer
1
1
Department of Psychiatry, Vic University Hospital, Vic, Spain
2
Institut Universitari d’Investigació en Atenció Primària Jordi Gol (IDIAP Jordi Gol), Barcelona, Spain
3
Universitat Autònoma de Barcelona, Bellaterra (Cerdanyola del Vallès), Spain
4
Department of Medical Sciences, School of Medicine, University of Girona, Girona, Spain
*
Author to whom correspondence should be addressed.
Clin. Pract. 2018, 8(1), 1044; https://doi.org/10.4081/cp.2018.1044
Submission received: 28 November 2017 / Revised: 28 November 2017 / Accepted: 2 January 2018 / Published: 26 January 2018

Abstract

Neuroleptic malignant syndrome (NMS) is a severe motor syndrome occurring as a consequence of neuroleptic treatment. We present a case of a 67-year-old Caucasian woman with a history of a major depressive disorder with psychotic features. During her third hospital admission, symptoms of autonomic instability, hyperpyrexia, severe extrapyramidal side effects, and delirium appeared, suggesting NMS due to concomitant treatment with risperidone and quetiapine, among other drugs. Despite several consecutive pharmacological treatments (lorazepam, bromocriptine and amantadine) and prompt initiation of electroconvulsive therapy (ECT), clinical improvement was observed only after combining bupropion with ECT. The symptoms that had motivated the admission gradually remitted and the patient was discharged home. Bupropion increases dopaminergic activity in both the nucleus accumbens and the prefrontal cortex. Therefore, from a physiopathological standpoint, bupropion has a potential role in treating NMS. However, there is scarce evidence supporting this approach and therefore future cases should be carefully considered.
Keywords: case report; neuroleptic malignant syndrome; major depressive disorder; electroconvulsive therapy; bupropion case report; neuroleptic malignant syndrome; major depressive disorder; electroconvulsive therapy; bupropion

Share and Cite

MDPI and ACS Style

Foguet-Boreu, Q.; Coll-Negre, M.; Serra-Millàs, M.; Cavalleria-Verdaguer, M. Neuroleptic Malignant Syndrome: A Case Responding to Electroconvulsive Therapy Plus Bupropion. Clin. Pract. 2018, 8, 1044. https://doi.org/10.4081/cp.2018.1044

AMA Style

Foguet-Boreu Q, Coll-Negre M, Serra-Millàs M, Cavalleria-Verdaguer M. Neuroleptic Malignant Syndrome: A Case Responding to Electroconvulsive Therapy Plus Bupropion. Clinics and Practice. 2018; 8(1):1044. https://doi.org/10.4081/cp.2018.1044

Chicago/Turabian Style

Foguet-Boreu, Quintí, Montse Coll-Negre, Montse Serra-Millàs, and Miquel Cavalleria-Verdaguer. 2018. "Neuroleptic Malignant Syndrome: A Case Responding to Electroconvulsive Therapy Plus Bupropion" Clinics and Practice 8, no. 1: 1044. https://doi.org/10.4081/cp.2018.1044

APA Style

Foguet-Boreu, Q., Coll-Negre, M., Serra-Millàs, M., & Cavalleria-Verdaguer, M. (2018). Neuroleptic Malignant Syndrome: A Case Responding to Electroconvulsive Therapy Plus Bupropion. Clinics and Practice, 8(1), 1044. https://doi.org/10.4081/cp.2018.1044

Article Metrics

Back to TopTop